Drugs / Peginterferon alfa-2a (PegIFNα-2a )
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT01288209 Background | Feb 2011 → Sep 2012 | chronic hepatitis C virus infection | Janssen Pharmaceutical K.K. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Peginterferon alfa-2a (PegIFNα-2a ) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01288209 ↗ |
| Route | Subcutaneous | “180 mcg once weekly injected subcutaneous (under the skin)” NCT01288209 ↗ |